However, the company's profit after tax was a loss of RON 10.88 million (€2.16 million). This represents a significant decline from the profit of RON 17.4 million (€3.46 million) recorded in the same period of 2024.

Meanwhile, pro-forma EBITDA saw significant growth, rising by 21.2% to RON 234 million (€47 million) over the previous year.

The company's strong performance was primarily driven by its hospital and laboratory divisions. The hospital division saw a 38% increase, attributed to recent investments in robotic surgery and the expansion of surgical procedures. Laboratories grew by 18%, while clinics advanced by 20% due to consistent demand for high-performance imaging services. MedLife also expanded its national and international presence by completing the acquisition of Routine Med and taking a majority stake in All Clinic in the Republic of Moldova.

“Our priorities in the first half of the year were focused on increasing operational activity in the recently acquired units and those inaugurated in 2024, as well as on the organic development of the entire Group, in a market with a moderate growth rate, as well as a less friendly macroeconomic environment. However, we have demonstrated that our growth engines work even in these conditions. We are confident that, with the implementation of the new reforms, the economy will gradually resume its growth trajectory, especially starting from mid-2026,” said Mihai Marcu, President and CEO of MedLife Group

In addition, MedLife has accelerated strategic investments in genetics and artificial intelligence.